Toxoplasmosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 48 Published: December 30, 2021 Report Code: GMDGDHC13189IDB

Toxoplasmosis is a disease that results from infection with the Toxoplasma gondii parasite. Symptoms include body aches, swollen lymph nodes, headache, fever, and fatigue. Risk factors include HIV/AIDS, chemotherapy, and immunosuppressant drugs. Treatment includes an antimalarial drug and antibiotics.

The Toxoplasmosis drugs in development market research report provide comprehensive information on the therapeutics under development for Toxoplasmosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Toxoplasmosis and features dormant and discontinued projects.

What are the key targets in the Toxoplasmosis pipeline products market?

The key targets in the Toxoplasmosis pipeline products market are Calcium Dependent Protein Kinase 1, Dihydrofolate Reductase, and Toxoplasma gondii Dihydrofolate Reductase.

Toxoplasmosis Pipeline Products Analysis Market by Targets

Toxoplasmosis Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the toxoplasmosis pipeline products market?

The key mechanisms of action in the toxoplasmosis pipeline products market are Calcium Dependent Protein Kinase 1 Inhibitor, Dihydrofolate Reductase Inhibitor, and Toxoplasma gondii Dihydrofolate Reductase Inhibitor.

Toxoplasmosis Pipeline Products Market Analysis by Mechanism of Actions

Toxoplasmosis Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

What are the key routes of administration in the toxoplasmosis pipeline products market?

The key routes of administration in the toxoplasmosis pipeline products market are oral, intramuscular, intravitreal, and nasal.

Toxoplasmosis Pipeline Products Market Analysis by Routes of Administration

Toxoplasmosis Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the key molecule types in the toxoplasmosis pipeline products market?

The key molecule types in the toxoplasmosis pipeline products market are small molecule, live attenuated vaccine, monoclonal antibody, mRNA vaccine, recombinant vector vaccine, and subunit vaccine.

Toxoplasmosis Pipeline Products Market Analysis by Molecule Type

Toxoplasmosis Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Which are the major companies in the Toxoplasmosis pipeline products market?

The major companies in the Toxoplasmosis pipeline products market are Vyera Pharmaceuticals LLC, AbbVie Inc, GlaxoSmithKline Plc, PGTx Ltd, Tiba Biotech LLC, and Vaxinano SE.

Toxoplasmosis Pipeline Products Market Analysis by Companies

Toxoplasmosis Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Key targets Calcium Dependent Protein Kinase 1, Dihydrofolate Reductase, and Toxoplasma gondii Dihydrofolate Reductase
Key mechanism of action Calcium Dependent Protein Kinase 1 Inhibitor, Dihydrofolate Reductase Inhibitor, and Toxoplasma gondii Dihydrofolate Reductase Inhibitor
Key routes of administration Oral, Intramuscular, Intravitreal, and Nasal
Key molecule type Small Molecule, Live Attenuated Vaccine, Monoclonal Antibody, mRNA Vaccine, Recombinant Vector Vaccine, and Subunit Vaccine
Major companies Vyera Pharmaceuticals LLC, AbbVie Inc, GlaxoSmithKline Plc, PGTx Ltd, Tiba Biotech LLC, and Vaxinano SE

Scope

  • The report provides a snapshot of the global therapeutic landscape of Toxoplasmosis
  • The report reviews pipeline therapeutics for Toxoplasmosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Toxoplasmosis therapeutics and enlists all their major and minor projects
  • The report assesses Toxoplasmosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news related to pipeline therapeutics for Toxoplasmosis

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Toxoplasmosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Toxoplasmosis pipeline depth and focus on Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from the pipeline

Key Players

AbbVie Inc

GlaxoSmithKline Plc

PGTx Ltd

Tiba Biotech LLC

Vaxinano SE

Vyera Pharmaceuticals LLC

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Toxoplasmosis – Overview

Toxoplasmosis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Toxoplasmosis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Toxoplasmosis – Companies Involved in Therapeutics Development

Monoclonal Antibodies for Ocular Toxoplasmosis – Drug Profile

Toxoplasmosis – Dormant Projects

Toxoplasmosis – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Toxoplasmosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Toxoplasmosis – Pipeline by AbbVie Inc, 2021

Toxoplasmosis – Pipeline by GlaxoSmithKline Plc, 2021

Toxoplasmosis – Pipeline by PGTx Ltd, 2021

Toxoplasmosis – Pipeline by Tiba Biotech LLC, 2021

Toxoplasmosis – Pipeline by Vaxinano SE, 2021

Toxoplasmosis – Pipeline by Vyera Pharmaceuticals LLC, 2021

Toxoplasmosis – Dormant Projects, 2021

List of Figures

List of Figures

Number of Products under Development for Toxoplasmosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

Frequently Asked Questions

Enquire Before Buying
$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.